Transira Therapeutics LLC, spun out of the University of Buffalo, develops an injectable, hormone-based drug for Type 2 diabetes patients to control their blood sugar while also facilitating weight loss. The company has developed a syntehtic form of the hormone oxyntomodulin, which helps increase insulin production as well as encouraging the body to increase its expenditure of energy and reduce food intake.
